{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:40:03Z","timestamp":1761676803893,"version":"3.40.5"},"reference-count":16,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuroimmunomodulation"],"published-print":{"date-parts":[[2019]]},"abstract":"<b><i>Introduction:<\/i><\/b> Multiple sclerosis (MS) is a neuroinflammatory autoimmune disease which involves the central nervous \u00adsystem. Although the primary cause of MS is obscure, effects of some cytokine and chemokine patterns in both innate and adaptive immune systems have been described. \u00ad<b><i>Objectives:<\/i><\/b> Since limited studies have examined the role of interleukin (IL)-11 and chemokine CCL27 in MS, we aimed to identify changes in IL-11 and CCL27 gene expression and serum levels in relapsing-remitting MS (RRMS) patients, treated with interferon (IFN)-\u03b2 and glatiramer acetate (GA). <b><i>Methods:<\/i><\/b> The serum level and gene expression of IL-11 and CCL27 were measured and compared between treatment-na\u00efve MS patients and RRMS patients who were treated with high-dose IFN-\u03b21a, low-dose IFN-\u03b21a, IFN-\u03b21b, and GA via enzyme-linked immunosorbent assay (ELISA) and quantitative real-time polymerase chain reaction. <b><i>Results<\/i><\/b>: A significant decrease was observed in the serum level of CCL27 in treatment-na\u00efve patients and IFN-\u03b21b-treated patients compared to the healthy controls. On the other hand, a significant increase was found in the protein level of CCL27 in low-dose and high-dose IFN-\u03b21a groups compared to the treatment-na\u00efve group. In addition, CCL27 gene expression was higher in patients treated with GA than in the treatment-na\u00efve group. There were no significant changes in the gene expression or protein level of IL-11 in all experimental groups. Additionally, a positive correlation was found between IL-11 and CCL-27. <b><i>Conclusion:<\/i><\/b> Our results suggest the inflammatory role of CCL27 in MS patients, while IFN-\u03b21a seems to play a compensatory role for this chemokine.<\/jats:p>","DOI":"10.1159\/000505098","type":"journal-article","created":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T22:01:08Z","timestamp":1579039268000},"page":"301-306","source":"Crossref","is-referenced-by-count":3,"title":["Assessment of CCL27 and IL-11 in Multiple Sclerosis Patients Treated with Interferon-\u03b2 and Glatiramer Acetate"],"prefix":"10.1159","volume":"26","author":[{"given":"Mohsen","family":"Ebrahimi\u00a0Monfared","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shima","family":"Shapoori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghasem","family":"Mosayebi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behzad","family":"Khansarinejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Ghazavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoud","family":"Rezagholizamenjany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2632-9889","authenticated-orcid":false,"given":"Ali","family":"Ganji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2020,1,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120227"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200737772"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1042\/bj3310695"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199808)41:8<1388::AID-ART7>3.0.CO;2-F"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nm0202-157"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/189638"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00531"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2017.05.023"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2174\/1871527317666180327122435"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.10.012"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2019.154911"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2010.04.019"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2004.09.011"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2289-06.2006"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900622"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401680"}],"container-title":["Neuroimmunomodulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/505098","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/505098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:17:14Z","timestamp":1745425034000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000505098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":16,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,2,26]]},"published-print":{"date-parts":[[2020,3,10]]}},"URL":"https:\/\/doi.org\/10.1159\/000505098","archive":["Portico"],"relation":{},"ISSN":["1021-7401","1423-0216"],"issn-type":[{"type":"print","value":"1021-7401"},{"type":"electronic","value":"1423-0216"}],"subject":[],"published":{"date-parts":[[2019]]}}}